Analytical validation and cross-validation of an NFAT-regulated gene expression assay for pharmacodynamic monitoring of therapy with calcineurin inhibitors

Background: Analysis of residual gene expression of the nuclear factor of activated T cell (NFAT)-regulated genes has been developed as a pharmacodynamic biomarker to monitor therapy with calcineurin inhibitors. The availability of commercial primer sets (Search-LC) and the well-established assay pr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Abdel-Kahaar, Emaad (VerfasserIn) , Giese, Thomas (VerfasserIn) , Sommerer, Claudia (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: August 26, 2016
In: Therapeutic drug monitoring
Year: 2016, Jahrgang: 38, Heft: 6, Pages: 711-716
ISSN:1536-3694
DOI:10.1097/FTD.0000000000000340
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1097/FTD.0000000000000340
Verlag, Volltext: http://journals.lww.com/drug-monitoring/Abstract/2016/12000/Analytical_Validation_and_Cross_Validation_of_an.10.aspx
Volltext
Verfasserangaben:Emaad Abdel-Kahaar, MSc, Thomas Giese, MD, Claudia Sommerer, MD, Hannah Rieger, PhD, Maria Shipkova, MD, and Eberhard Wieland, MD

MARC

LEADER 00000caa a2200000 c 4500
001 1564122220
003 DE-627
005 20230427142047.0
007 cr uuu---uuuuu
008 171005s2016 xx |||||o 00| ||eng c
024 7 |a 10.1097/FTD.0000000000000340  |2 doi 
035 |a (DE-627)1564122220 
035 |a (DE-576)494122226 
035 |a (DE-599)BSZ494122226 
035 |a (OCoLC)1340980241 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Abdel-Kahaar, Emaad  |d 1981-  |e VerfasserIn  |0 (DE-588)1127559583  |0 (DE-627)881971960  |0 (DE-576)485247704  |4 aut 
245 1 0 |a Analytical validation and cross-validation of an NFAT-regulated gene expression assay for pharmacodynamic monitoring of therapy with calcineurin inhibitors  |c Emaad Abdel-Kahaar, MSc, Thomas Giese, MD, Claudia Sommerer, MD, Hannah Rieger, PhD, Maria Shipkova, MD, and Eberhard Wieland, MD 
264 1 |c August 26, 2016 
300 |a 6 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 05.10.2017 
520 |a Background: Analysis of residual gene expression of the nuclear factor of activated T cell (NFAT)-regulated genes has been developed as a pharmacodynamic biomarker to monitor therapy with calcineurin inhibitors. The availability of commercial primer sets (Search-LC) and the well-established assay protocol makes this biomarker a promising candidate to be used clinically in different laboratories. However, implementation of the method in routine practice requires analytical robustness and comparable results across laboratories. Therefore, a protocol originally established at the Institute of Immunology, Heidelberg was verified at the Institute of Laboratory Medicine, Klinikum Stuttgart, and a comparison study was conducted between the 2 laboratories. Methods: For the analytical verification, whole blood samples of healthy individuals were incubated with tacrolimus in vitro. Linearity, imprecision, and limit of quantification, as well as sample stability, were investigated. For interlaboratory comparison, samples of patients under cyclosporine A therapy were analyzed in Heidelberg and then reanalyzed in Stuttgart within 24 hours. Results: Tacrolimus (6.25-50 mcg/L) decreased the expression of NFAT-regulated genes in vitro dose dependently (15%-89%). Within- and between-assay coefficient of variations (n = 6 each) were <17%. The limit of quantification was <200 cDNA copies for each of the interleukin-2, interferon-γ, and granulocyte-macrophage colony-stimulating factor genes. Samples were stable for 24 hours. Interlaboratory comparison using patient samples correlated well (r = 0.951) but showed an inconsistent bias depending on the magnitude of residual gene expression.Conclusions: The assay can be set up with a satisfactory analytical performance in a routine molecular biological laboratory and shows comparable results between laboratories. The reproducibility of the NFAT-regulated gene expression assay across laboratories can facilitate the implementation of this assay for pharmacodynamic routine monitoring of calcineurin inhibitors in different centers. 
700 1 |a Giese, Thomas  |d 1962-  |e VerfasserIn  |0 (DE-588)143133543  |0 (DE-627)704399075  |0 (DE-576)333724496  |4 aut 
700 1 |a Sommerer, Claudia  |d 1971-  |e VerfasserIn  |0 (DE-588)121857654  |0 (DE-627)705680002  |0 (DE-576)292921829  |4 aut 
773 0 8 |i Enthalten in  |t Therapeutic drug monitoring  |d Philadelphia, Pa. : Lippincott Williams & Wilkins, 1979  |g 38(2016), 6, Seite 711-716  |h Online-Ressource  |w (DE-627)330079239  |w (DE-600)2048919-5  |w (DE-576)094529795  |x 1536-3694  |7 nnas  |a Analytical validation and cross-validation of an NFAT-regulated gene expression assay for pharmacodynamic monitoring of therapy with calcineurin inhibitors 
773 1 8 |g volume:38  |g year:2016  |g number:6  |g pages:711-716  |g extent:6  |a Analytical validation and cross-validation of an NFAT-regulated gene expression assay for pharmacodynamic monitoring of therapy with calcineurin inhibitors 
856 4 0 |u http://dx.doi.org/10.1097/FTD.0000000000000340  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u http://journals.lww.com/drug-monitoring/Abstract/2016/12000/Analytical_Validation_and_Cross_Validation_of_an.10.aspx  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20171005 
993 |a Article 
994 |a 2016 
998 |g 121857654  |a Sommerer, Claudia  |m 121857654:Sommerer, Claudia  |d 50000  |e 50000PS121857654  |k 0/50000/  |p 3 
998 |g 143133543  |a Giese, Thomas  |m 143133543:Giese, Thomas  |d 910000  |d 911600  |e 910000PG143133543  |e 911600PG143133543  |k 0/910000/  |k 1/910000/911600/  |p 2 
999 |a KXP-PPN1564122220  |e 2982793539 
BIB |a Y 
SER |a journal 
JSO |a {"person":[{"display":"Abdel-Kahaar, Emaad","family":"Abdel-Kahaar","role":"aut","given":"Emaad"},{"given":"Thomas","role":"aut","display":"Giese, Thomas","family":"Giese"},{"given":"Claudia","role":"aut","display":"Sommerer, Claudia","family":"Sommerer"}],"language":["eng"],"note":["Gesehen am 05.10.2017"],"origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"August 26, 2016"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title_sort":"Analytical validation and cross-validation of an NFAT-regulated gene expression assay for pharmacodynamic monitoring of therapy with calcineurin inhibitors","title":"Analytical validation and cross-validation of an NFAT-regulated gene expression assay for pharmacodynamic monitoring of therapy with calcineurin inhibitors"}],"recId":"1564122220","physDesc":[{"extent":"6 S."}],"name":{"displayForm":["Emaad Abdel-Kahaar, MSc, Thomas Giese, MD, Claudia Sommerer, MD, Hannah Rieger, PhD, Maria Shipkova, MD, and Eberhard Wieland, MD"]},"id":{"doi":["10.1097/FTD.0000000000000340"],"eki":["1564122220"]},"relHost":[{"disp":"Analytical validation and cross-validation of an NFAT-regulated gene expression assay for pharmacodynamic monitoring of therapy with calcineurin inhibitorsTherapeutic drug monitoring","language":["eng"],"part":{"text":"38(2016), 6, Seite 711-716","pages":"711-716","year":"2016","volume":"38","extent":"6","issue":"6"},"origin":[{"publisherPlace":"Philadelphia, Pa. ; [Erscheinungsort nicht ermittelbar]","dateIssuedDisp":"1979-","publisher":"Lippincott Williams & Wilkins ; Ovid","dateIssuedKey":"1979"}],"note":["Gesehen am 11.06.2019"],"type":{"bibl":"periodical","media":"Online-Ressource"},"title":[{"title_sort":"Therapeutic drug monitoring","subtitle":"official journal of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology","title":"Therapeutic drug monitoring"}],"recId":"330079239","pubHistory":["1.1979 -"],"physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["330079239"],"issn":["1536-3694"],"zdb":["2048919-5"]}}]} 
SRT |a ABDELKAHAAANALYTICAL2620